AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
* Six month, double-blind, placebo-controlled study of 174 patients (mean age 74 years) randomized to combined docosahexaenoic acid/eicosapentaenoic acid (DHA/EPA) fatty acid supplements or placebo, followed by 6 months of open DHA/EPA treatment
* Omega-3 fatty acid supplementation does not appear to delay the rate of cognitive decline in patients with mild to moderate AD; in a small subgroup of subjects with MMSE scores 27 or higher, positive effects were observed in the active treatment arm
In a new study investigating the effects of omega-3 fatty acid supplementation in elderly patients with mild to moderate Alzheimer's disease (AD), Swedish researchers found that the rate of cognitive decline in the active-treatment group was not reduced. However, there were positive effects of omega-3 fatty acid in some patients with …